Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

Volume: 363, Issue: 8, Pages: 711 - 723
Published: Aug 18, 2010
Abstract
Background An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab — which blocks cytotoxic T-lymphocyte–associated antigen 4 to potentiate an antitumor T-cell response — administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. Methods A total of 676...
Paper Details
Title
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
Published Date
Aug 18, 2010
Volume
363
Issue
8
Pages
711 - 723
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.